| 2023年中报 | 2022年年报 | 2022年中报 | |
|---|---|---|---|
| 营业收入(元) | |||
| 仿制药原料药及中间体(元) | 1,066,156,907.91 | - | 1,269,211,569.45 |
| 制剂(元) | 42,778,016.85 | - | 10,152,917.11 |
| CMO(元) | 231,001,664.79 | - | 184,687,726.64 |
| 降血糖类原料药及中间体(元) | - | 110,847,268.86 | - |
| 降血压类原料药及中间体(元) | - | 1,991,490,006.87 | - |
| 抗病毒类原料药及中间体(元) | - | 72,118,137.56 | - |
| 抗凝血类原料药及中间体(元) | - | 204,257,534.88 | - |
| 抗哮喘类原料药及中间体(元) | - | 138,624,863.82 | - |
| 其他主营业务(元) | - | - | 9,881,537.54 |
| 其他(元) | 6,440,246.90 | 149,340,659.81 | 9,881,537.54 |
| 营业成本(元) | |||
| 仿制药原料药及中间体(元) | 698,554,921.84 | - | 952,438,279.23 |
| 制剂(元) | 13,572,875.13 | - | 5,020,182.56 |
| CMO(元) | 95,488,745.04 | - | 93,943,391.38 |
| 降血糖类原料药及中间体(元) | - | - | - |
| 降血压类原料药及中间体(元) | - | 1,469,321,890.66 | - |
| 抗病毒类原料药及中间体(元) | - | - | - |
| 抗凝血类原料药及中间体(元) | - | 87,054,332.03 | - |
| 抗哮喘类原料药及中间体(元) | - | - | - |
| 其他主营业务(元) | - | - | 8,386,868.30 |
| 其他(元) | - | - | 8,386,868.30 |
| 毛利(元) | |||
| 仿制药原料药及中间体(元) | 367,601,986.07 | - | 316,773,290.22 |
| 制剂(元) | 29,205,141.72 | - | 5,132,734.55 |
| CMO(元) | 135,512,919.75 | - | 90,744,335.26 |
| 降血糖类原料药及中间体(元) | - | - | - |
| 降血压类原料药及中间体(元) | - | 522,168,116.21 | - |
| 抗病毒类原料药及中间体(元) | - | - | - |
| 抗凝血类原料药及中间体(元) | - | 117,203,202.85 | - |
| 抗哮喘类原料药及中间体(元) | - | - | - |
| 其他主营业务(元) | - | - | 1,494,669.24 |
| 其他(元) | - | - | 1,494,669.24 |
| 毛利率(%) | |||
| 仿制药原料药及中间体(%) | 34.48 | - | 24.96 |
| 制剂(%) | 68.27 | - | 50.55 |
| CMO(%) | 58.66 | - | 49.13 |
| 降血糖类原料药及中间体(%) | - | - | - |
| 降血压类原料药及中间体(%) | - | 26.22 | - |
| 抗病毒类原料药及中间体(%) | - | - | - |
| 抗凝血类原料药及中间体(%) | - | 57.38 | - |
| 抗哮喘类原料药及中间体(%) | - | - | - |
| 其他主营业务(%) | - | - | 15.13 |
| 其他(%) | - | - | 15.13 |
| 收入构成(%) | |||
| 仿制药原料药及中间体(%) | 79.19 | - | 85.54 |
| 制剂(%) | 3.18 | - | 0.68 |
| CMO(%) | 17.16 | - | 12.45 |
| 降血糖类原料药及中间体(%) | - | 4.16 | - |
| 降血压类原料药及中间体(%) | - | 74.68 | - |
| 抗病毒类原料药及中间体(%) | - | 2.70 | - |
| 抗凝血类原料药及中间体(%) | - | 7.66 | - |
| 抗哮喘类原料药及中间体(%) | - | 5.20 | - |
| 其他主营业务(%) | - | - | 0.67 |
| 其他(%) | 0.48 | 5.60 | 0.67 |
| 毛利构成(%) | |||
| 仿制药原料药及中间体(%) | 69.06 | - | 76.21 |
| 制剂(%) | 5.49 | - | 1.23 |
| CMO(%) | 25.46 | - | 21.83 |
| 降血糖类原料药及中间体(%) | - | 0.00 | - |
| 降血压类原料药及中间体(%) | - | 81.67 | - |
| 抗病毒类原料药及中间体(%) | - | 0.00 | - |
| 抗凝血类原料药及中间体(%) | - | 18.33 | - |
| 抗哮喘类原料药及中间体(%) | - | 0.00 | - |
| 其他主营业务(%) | - | - | 0.36 |
| 其他(%) | 0.00 | 0.00 | 0.36 |